Ignite Creation Date:
2024-05-05 @ 5:15 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00412113
Status:
COMPLETED
Last Update Posted:
2021-02-11
First Post:
2006-12-13
Brief Title:
A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk
Sponsor:
Pfizers Upjohn has merged with Mylan to form Viatris Inc
Organization:
Pfizer
Study Overview
Official Title:
A 6-Week Prospective Randomized Double-Blind Double-Dummy Phase IV Clinical Trial Designed to Evaluate the Efficacy of an Aggressive Multi-Risk Factor Management Strategy With Caduet A3841045 Versus a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensive Subjects With Additional Risk Factors
Status:
COMPLETED
Status Verified Date:
2021-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TOGETHER
Brief Summary:
The purpose of this study is to investigate whether an aggressive multi-risk factor management strategy Caduet plus therapeutic lifestyle changes TLC regimen will result in greater percentage of patients achieving blood pressure and low density lipoprotein cholesterol LDL-C goals compared with a Joint National Committee 7 National Cholesterol Education Program Adult Treatment Panel III JNC 7NCEP ATP III guideline-based approach Norvasc plus TLC regimen after 6 weeks of treatment in primary prevention subjects with hypertension and additional risk factors including dyslipidemia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None